Fairbanks Capital Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Fairbanks Capital Management’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-553	Closed	-$20K	–	52
2019 Q1	$20K	Hold	553	–	–	0.02%	30
2018 Q4	$20K	Sell	553 -941	-63%	-$79.3K	0.02%	31
2018 Q3	$233K	Sell	1,494 -67	-4%	-$9.92K	0.23%	29
2018 Q2	$208K	Hold	1,561	–	–	0.24%	29
2018 Q1	$386K	Hold	1,561	–	–	0.39%	27
2017 Q4	$433K	Buy	1,561 +7	+0.5%	+$2.67K	0.4%	28
2017 Q3	$629K	Hold	1,554	–	–	0.61%	25
2017 Q2	$921K	Hold	1,554	–	–	0.86%	22
2017 Q1	$956K	Hold	1,554	–	–	0.94%	17
2016 Q4	$315K	Sell	1,554 -14	-0.9%	-$3.18K	0.33%	24
2016 Q3	$411K	Buy	1,568 +14	+0.9%	+$4.29K	0.44%	23
2016 Q2	$464K	Buy	+1,554	New	+$546K	0.56%	20

Other funds holding VYNT

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return

Diker Management New York $112M AUM 59.78% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Fairbanks Capital Management's VYNT Position: Q2 2019 in Review

Fairbanks Capital Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2019, closing a stake of 553 shares — an estimated $20K sold.

Fairbanks Capital Management first reported a position in VYNT in Q2 2016 and held it in 12 quarters. The position peaked at $956K in Q1 2017. 23 funds tracked by Wall St. Rank hold VYNT as of Q2 2019.

Fairbanks Capital Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Fairbanks Capital Management sold 553 Vyant Bio, Inc. Common Stock shares in Q2 2019, an estimated $20K.
Fairbanks Capital Management first reported a position in Vyant Bio, Inc. Common Stock in Q2 2016 and held it in 12 quarters.
Fairbanks Capital Management's Vyant Bio, Inc. Common Stock position peaked at $956K in Q1 2017.
23 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2019.

Based on Fairbanks Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.